Publication | Open Access
A first-in-class and a fished out anticancer platinum compound: cis-[PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub>] and cis-[PtI<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub>] compared for their reactivity towards DNA model systems
36
Citations
35
References
2016
Year
Molecular BiologyChemical BiologyMedicinal ChemistryAnticancer Platinum CompoundNucleic Acid ChemistryOncologyOverall ReactivityAnti-cancer AgentRadiation OncologyTumour Cell LinesCancer ResearchInorganic ChemistryBiochemistryOligonucleotideCancer TreatmentDiiodido AnalogueBiomolecular EngineeringNatural SciencesCoordination ComplexMolecular ComplexMedicineDrug Discovery
Contrary to what was believed for many years, cis-PtI2(NH3)2, the diiodido analogue of cisplatin, displays high in vitro antiproliferative activity toward a set of tumour cell lines, overcoming resistance to cisplatin in a platinum-resistant cancer cell line. In the context of a general reappraisal of iodinated Pt(ii) derivatives, aiming at a more systematic evaluation of their chemical and biological profiles, here we report on the reactivity of cis-PtI2(NH3)2 with selected DNA model systems, in single, double strand or G-quadruplex form, using cisplatin as a control. A combined approach has been exploited in this study, including circular dichroism (CD), UV-visible spectroscopy and electrospray mass spectrometry (ESI-MS) analyses. The data reveal that cis-PtI2(NH3)2 shows an overall reactivity towards the investigated oligonucleotides significantly higher than cisplatin.
| Year | Citations | |
|---|---|---|
Page 1
Page 1